Thymidine Phosphorylase in Cancer; Enemy or Friend?

Overview

Journal Cancer Microenviron

Publisher Springer

Specialty Oncology

Date 2015 Aug 24

PMID 26298314

Citations 37

Authors

Yasir Y Elamin

Shereen Rafee

Nemer Osman

Kenneth J O Byrne

Kathy Gately

Affiliations

Soon will be listed here.

Abstract

Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important role in the pyrimidine pathway.TP catalyzes the conversion of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate (dRib-1-P). Although this reaction is reversible, the main metabolic function of TP is catabolic. TP is identical to the angiogenic factor platelet-derived endothelial-cell growth factor (PD-ECGF). TP is overexpressed in several human cancers in response to cellular stressful conditions like hypoxia, acidosis, chemotherapy and radiotherapy. TP has been shown to promote tumor angiogenesis, invasion, metastasis, evasion of the immune-response and resistance to apoptosis. Some of the biological effects of TP are dependent on its enzymatic activity, while others are mediated through cytokines like interleukin 10 (IL-10), basic fibroblast growth factor (bFGF) and tumour necrosis factor α (TNFα). Interestingly, TP also plays a role in cancer treatment through its role in the conversion of the oral fluoropyrimidine capecitabine into its active form 5-FU. TP is a predictive marker for fluoropyrimidine response. Given its various biological functions in cancer progression, TP is a promising target in cancer treatment. Further translational research is required in this area.

Citing Articles

Eradication of Cancer Cells Using Doxifluridine and Mesenchymal Stem Cells Expressing Thymidine Phosphorylase.

Wang X, Peng I, Peng C Bioengineering (Basel). 2025; 11(12.

PMID: 39768012 PMC: 11726915. DOI: 10.3390/bioengineering11121194.

Identification and role of differentially expressed genes/proteins between pulmonary tuberculosis patients and controls across lung tissues and blood samples.

Li Q, Maierheba K Immun Inflamm Dis. 2024; 12(7):e1350.

PMID: 39023413 PMC: 11256885. DOI: 10.1002/iid3.1350.

Oxidative Stress in Breast Cancer: A Biochemical Map of Reactive Oxygen Species Production.

Belskaya L, Dyachenko E Curr Issues Mol Biol. 2024; 46(5):4646-4687.

PMID: 38785550 PMC: 11120394. DOI: 10.3390/cimb46050282.

Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.

Li R, Zhou H, Zeng D, Jiang S, Liu W, Fruhling P J Gastrointest Oncol. 2024; 15(2):612-629.

PMID: 38756644 PMC: 11094502. DOI: 10.21037/jgo-24-98.

A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.

Zou J, Wang Y, Xu J, Li J, Wang T, Zhang Y J Clin Med. 2024; 13(1).

PMID: 38202064 PMC: 10779919. DOI: 10.3390/jcm13010057.

References

Pula G, Mayr U, Evans C, Prokopi M, Vara D, Yin X . Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res. 2008; 104(1):32-40. DOI: 10.1161/CIRCRESAHA.108.182261. View

Fox S, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter K . Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol. 1995; 176(2):183-90. DOI: 10.1002/path.1711760212. View

Aschele C, Sobrero A, Faderan M, Bertino J . Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992; 52(7):1855-64. View

FRIEDKIN M, Roberts D . The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem. 1954; 207(1):245-56. View

Sivridis E, Giatromanolaki A, Koukourakis M, Bicknell R, Harris A, Gatter K . Thymidine phosphorylase expression in normal and hyperplastic endometrium. J Clin Pathol. 2000; 53(9):704-8. PMC: 1731246. DOI: 10.1136/jcp.53.9.704. View

Sadahiro S, Suzuki T, Tanaka A, Okada K, Nagase H, Uchida J . Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol. 2012; 70(2):285-91. DOI: 10.1007/s00280-012-1909-8. View

Yang Q, Yoshimura G, Mori I, Sakurai T, Kakudo K . Thymidine phosphorylase and breast carcinoma. Anticancer Res. 2002; 22(4):2355-60. View

Ikeda R, Che X, Ushiyama M, Yamaguchi T, Okumura H, Nakajima Y . 2-Deoxy-D-ribose inhibits hypoxia-induced apoptosis by suppressing the phosphorylation of p38 MAPK. Biochem Biophys Res Commun. 2006; 342(1):280-5. DOI: 10.1016/j.bbrc.2006.01.142. View

Lu M, Gao J, Wang X, Shen L . Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin. Chin J Cancer Res. 2013; 23(4):288-94. PMC: 3551314. DOI: 10.1007/s11670-011-0288-8. View

10.

Liekens S, Bronckaers A, Belleri M, Bugatti A, Sienaert R, Ribatti D . The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist. Mol Cancer Ther. 2012; 11(4):817-29. DOI: 10.1158/1535-7163.MCT-11-0738. View

11.

Brown N, Bicknell R . Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J. 1998; 334 ( Pt 1):1-8. PMC: 1219653. DOI: 10.1042/bj3340001. View

12.

Ikeda R, Tajitsu Y, Iwashita K, Che X, Yoshida K, Ushiyama M . Thymidine phosphorylase inhibits the expression of proapoptotic protein BNIP3. Biochem Biophys Res Commun. 2008; 370(2):220-4. DOI: 10.1016/j.bbrc.2008.03.067. View

13.

Stenman G, Sahlin P, Dumanski J, Hagiwara K, Ishikawa F, Miyazono K . Regional localization of the human platelet-derived endothelial cell growth factor (ECGF1) gene to chromosome 22q13. Cytogenet Cell Genet. 1992; 59(1):22-3. DOI: 10.1159/000133191. View

14.

Trempolec N, Dave-Coll N, Nebreda A . SnapShot: p38 MAPK signaling. Cell. 2013; 152(3):656-656.e1. DOI: 10.1016/j.cell.2013.01.029. View

15.

Fox S, Engels K, Comley M, Whitehouse R, Turley H, Gatter K . Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol. 1997; 8(3):271-5. DOI: 10.1023/a:1008280110558. View

16.

Stark M, Bram E, Akerman M, Mandel-Gutfreund Y, Assaraf Y . Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistance. J Biol Chem. 2010; 286(5):3741-54. PMC: 3030376. DOI: 10.1074/jbc.M110.163444. View

17.

Ciccolini J, Evrard A, Cuq P . Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents. 2004; 4(2):71-81. DOI: 10.2174/1568011043482089. View

18.

Shaw T, Smillie R, Miller A, MacPhee D . The role of blood platelets in nucleoside metabolism: regulation of platelet thymidine phosphorylase. Mutat Res. 1988; 200(1-2):117-31. DOI: 10.1016/0027-5107(88)90075-9. View

19.

Wang L, Huang X, Chen Y, Jin X, Li Q, Yi T . Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma. Eur J Surg Oncol. 2012; 38(7):568-73. DOI: 10.1016/j.ejso.2012.04.008. View

20.

Ruckhaberle E, Karn T, Engels K, Turley H, Hanker L, Muller V . Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data. Eur J Cancer. 2009; 46(3):549-57. DOI: 10.1016/j.ejca.2009.11.020. View